Breast Cancer Clinical Trial

Early Detection of Breast Cancer in Women With Suspicious Mammograms

Summary

This is a non-treatment study. It will not involve the use of any investigational drug or device. Potential participants will be enrolled through direct contact with collaborating clinical sites when the patient's annual 3D mammogram report yields a BIRADS rating of 4-5. The clinical Investigators or a member of their staff will conduct consent discussion once a suspicious mammogram report is identified or if a patient is referred for imaging of a suspicious area in the breast. After consenting the participant will be asked to donate a blood sample, a saliva sample, medical records pertaining to the suspicious mammogram report and a medical history questionnaire. The participants will be followed after one year to capture progression or resolution of their suspicious mammogram report. After a biopsy confirms the diagnosis of cancer or benign lesion, a recut sample of the tissue may be requested for research.

View Full Description

Full Description

Breast cancer is a leading cause of cancer mortality in women worldwide. According to estimates, approximately 46,000 women in the United States, and 130,000 women in the European Union, die due to breast cancer yearly. Early detection is of paramount importance in reducing mortality from this major public health burden. Screening mammography has been shown to reduce breast cancer mortality by 20% to 35% in women aged 40 to 69 years. Detection of small volume breast cancer at early stages is associated with a 10-year disease-free survival rate as high as 98% in patients with pT1a,bN0M0 tumors (measuring 1 cm or less, with disease-free axillary lymph nodes and no distant metastasis). The assumption that early diagnosis will lead to improved treatment outcomes has driven the search for diagnostic biomarkers.

Despite this enthusiasm, a biomarker for stage I breast cancer has been elusive. The predictive value of mammography declines in cohorts of patients with denser breast tissue and smaller lesions, and recent studies have indicated that the small amount of biomarker molecules emanating from a breast tumor of less than 1 cm is well below the sensitivity of detection for current analytical methods. In addition, biomarkers in body fluids are highly perishable. Biomarkers break down during collection, transport and storage due to endogenous degradative enzymes yielding false negatives. Thus there is a significant need for new technologies that will a) identify and measure low abundance biomarkers (less than 1 nanogram/mL), and b) is low cost and can be seamlessly integrated into the clinical workflow.

Primary Objective:

The primary goal of this study is to a) experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.

Secondary Objectives:

Determine percent accuracy of breast cancer diagnosis in the context of 3D mammographically (screen detected) tumors.
Determine percent precision of cancer diagnosis in the context of 3D mammographically (screen detected) tumors.
Discover additional protein markers of early stage breast cancer that distinguish these tumors from benign lesions identified by mammography by comparing protein markers between patients with invasive cancer vs. benign tumors as determined by biopsy.
Additionally compare protein markers between patients with invasive cancer and pre-invasive neoplasms as determined by biopsy.
Bank samples for future research and sequencing.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women who receive a suspicious mammogram report or are scheduled to receive testing for suspect breast area, with a subsequent biopsy to confirm diagnosis
Willingness and ability to donate biospecimens for the purpose of propelling research.
Participants aged ≥ 18.

Exclusion Criteria:

Individuals under 18 years of age or over 89 years of age.
A known history of breast cancer.
A diagnosis or history of any other type of cancer.
Participants who are male.

Study is for people with:

Breast Cancer

Estimated Enrollment:

270

Study ID:

NCT03147430

Recruitment Status:

Recruiting

Sponsor:

Sentara Norfolk General Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Dorothy G Hoefer Comprehensive Breast Center
Newport News Virginia, 23606, United States More Info
Jennifer Newman
Contact
757-388-2406
[email protected]
Richard Hoefer, DO
Principal Investigator
Sentara Norfolk General Breast Center
Norfolk Virginia, 23507, United States More Info
Jennifer Newman
Contact
757-388-2406
[email protected]
Mary Jo Bradley
Contact
757-388-5629
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

270

Study ID:

NCT03147430

Recruitment Status:

Recruiting

Sponsor:


Sentara Norfolk General Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.